Search clinical trials for: Anlotinib Plus Docetaxel

Total 8160 results

Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） (ACDFNSCLC)

Non Small Cell Lung Cancer
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Anlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
Hellenic Cooperative Oncology Group

Terminated

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

Advanced Non-Small Cell Lung Cancer

Greece
Dutch Society of Physicians for Pulmonology and...

Completed

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (NVALT10)

Carcinoma, Non-Small-Cell Lung

Netherlands
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Small Cell Lung Cancer Limited Stage

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Terminated

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Non Squamous Non Small Cell Lung

China
The First People's Hospital of Lianyungang
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Lung Neoplasms | Anlotinib | Docetaxel | S-1 | Pemetrexed

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaborators

Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (ALTER-L024)

Non-small Cell Lung Cancer

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Infinity Pharmaceuticals, Inc.

Completed

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania
Hospital Arnau de Vilanova

Unknown

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Non-Small Cell Lung Cancer

Spain
Cancer Institute and Hospital, Chinese Academy...

Unknown

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Breast Cancer Recurrent

China
Boehringer Ingelheim

Completed

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Germany, China, Israel, Denmark, Belgium, Switzerland, Croatia, Poland, Romania, South Africa, Czechia, Greece, Portugal, United Kingdom, India, Italy, Austria, Belarus, Ukraine, Russian Federation, France, Bulgaria, Georgia, Korea... and more
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (NEOPCOSCC)

Oral Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Optimal Health Research

Completed

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Breast Cancer | Lung Cancer | Prostate Cancer

United States
University Hospital, Limoges
Hoffmann-La Roche

Completed

Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer (TARSEQ)

Non Small Cell Lung Cancer

France
National Taiwan University Hospital

Unknown

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca (Oncology)

Non-small Cell Lung Cancer(NSCLC)

Taiwan
Hoffmann-La Roche

Completed

A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Non-Squamous Non-Small Cell Lung Cancer

Italy
Meir Medical Center

Completed

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Non-Small Cell Lung Cancer

Israel
Jonsson Comprehensive Cancer Center
Aventis Pharmaceuticals; Genentec

Completed

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Prostate Cancer

United States
Mirati Therapeutics Inc.

Terminated

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Advanced Malignancies, Non-small Cell Lung Cancer

United States
Paula Silverman, MD
National Cancer Institute (NCI)

Completed

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Breast Cancer

United States
University of Texas Southwestern Medical Center
Genentech, Inc.; Celgene

Completed

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer | Metastatic Cancer

United States
University of California, Davis
National Cancer Institute (NCI); Genentech, Inc.; Aventis Pharmaceuticals

Completed

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center

Completed

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
National Cancer Institute (NCI)

Completed

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of... and other conditions

United States
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
National Taiwan University Hospital

Completed

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

NSCLC

Taiwan

Search clinical trials for: Anlotinib Plus Docetaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations